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Abstract – As an extension of our project aimed at the search for new chemotherapeutic 
agents against Chagas disease and toxoplasmosis, several 1,1-bisphosphonates were 
designed, synthesized and biologically evaluated against Trypanosoma cruzi and 
Toxoplasma gondii, the etiologic agents of these diseases, respectively. In particular, 
and based on the antiparasitic activity exhibited by 2-alkylaminoethyl-1,1-
bisphosphonates targeting farnesyl diphosphate synthase, a series of linear 2-
alkylaminomethyl-1,1-bisphosphonic acids (compounds 21−33), that is, the position of 
the amino group was one carbon closer to the gem-phosphonate moiety, were evaluated 
as growth inhibitors against the clinically more relevant dividing form (amastigotes) of 
T. cruzi. Although all of these compounds resulted to be devoid of antiparasitic activity, 
these results were valuable for a rigorous SAR study. In addition, unexpectedly, the 
synthetic designed 2-cycloalkylaminoethyl-1,1-bisphosphonic acids 47−49 were free of 
antiparasitic activity. Moreover, long chain sulfur-containing 1,1-bisphosphonic acids, 
such as compounds 54−56, 59, turned out to be nanomolar growth inhibitors of 
tachyzoites of T. gondii. As many bisphosphonate-containing molecules are FDA-
approved drugs for the treatment of bone resorption disorders, their potential 




American Trypanosomiasis (Chagas disease) is a chronic zoonosis produced by 
the kinetoplastid parasite Trypanosoma cruzi, is the major parasitic disease burden of 
the American continent, and can be considered as one of the most important diseases in 
the world together with malaria and schistosomiasis.1 The commonly affected organ is 
the heart with myocarditis and the central nervous system is also commonly attacked.2–4 
In addition, the second most common symptoms are the so-called megavisceras; 
therefore, the most commonly affected system is the digestive tract. The current 
chemotherapy is still deficient and based on two empirically-discovered drugs: 
nifurtimox (Lampit®, Bayer - El Salvador), which is available under a CDC 
investigational protocols5 and benznidazole (Abarax®, Elea - Argentina), which was a 
recently FDA-approved drug but for pediatric use only.5 
(https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm573942.htm ). In 
most of endemic countries benznidazole is a drug of choice to treat the acute phase of 
the infection and is indicated to treat the chronic phase even with low efficiency.6 As 
both of these drugs are associated to long term treatment and severe side effects there is 
a serious necessity to develop new safe drugs based on the knowledge of the 
biochemistry and physiology of these microorganisms. In AIDS-infected patients, 
chronic suppressive therapy is required and this is associated with neurotoxicity due to 
the drugs.
On the other hand, T. gondii is an opportunistic protozoan parasite that is 
responsible for toxoplasmosis.7 T. gondii is able to infect a wide range of hosts, 
particularly humans and warm-blooded animals.8 Toxoplasmosis is positively one of the 
most prevalent parasitic diseases affecting close to one billion people worldwide.9 
Particularly, this parasite can cause mortality among immunocompromised individuals 
such as AIDS patients, organ transplant recipients, as well as congenitally infected 
children. Toxoplasmosis may lead to severe central nervous system disease. As occurs 
with Chagas disease treatment, the current chemotherapy for toxoplasmosis is still 
deficient as well.10
Several enzymes of the isoprenoid pathway, involved in the synthesis of sterols 
and farnesyl diphosphate, have been reported to be excellent drug targets against 
trypanosomatids.11,12 Regardless of their different structures and functional diversity, all 
  
isoprenoids have a common precursor: isopentenyl diphosphate, and its isomer, 
dimethylallyl diphosphate. In T. cruzi, isopentenyl diphosphate is biosynthesized 
exclusively via the so-called mevalonate pathway, which has the 3-hydroxy-3-
methylglutaryl-CoA (HMG-CoA) reductase as the fundamental directing enzyme. 
Although T. cruzi takes up sterols from its mammalian host (largely cholesterol), it has 
an essential requirement for de novo sterol biosynthesis in all stages of its life cycle and 
is extremely susceptible to sterol biosynthesis inhibitors. On the other hand, T. gondii 
lacks the mevalonate pathway and employs an apicoplast localized biosynthesis, 
prokaryotic-type, 1-deoxy-D-xylulose-5-phosphate (DOXP) pathway, instead.13,14 The 
DOXP pathway is not present in the host. In addition, as T. gondii does not synthesize 
cholesterol, which is taken from the host indicating that inhibitors of the host isoprenoid 
biosynthesis would be putative growth inhibitors of T. gondii.15 Certainly, mevalonate 
pathway inhibitors are able to control proliferation of a number of Apicomplexan 
parasites such as Babesia divergens,16 Plasmodium falciparum,17 Cryptosporidium 
parvum,18 and T. gondii,19 indicating that parasites lacking the mevalonate pathway are 
reliant on host precursors of isoprenoid biosynthesis. Interestingly, the synergistic effect 
of  host and parasite isoprenoid pathway inhibitors has been reported.20 For example, 
the used of two commonly used drugs, zoledronic acid and atorvastatin, exhibited a 
strong synergism in modulating T. gondii multiplication.20 It would be possible to take 
advantage the fact of T. cruzi and T. gondii proliferate intracellularly to be used as a 
model for two major groups of parasites: trypanosomatids (T. cruzi, African 
trypanosomes, Leishmania spp) and Apicomplexan (P. falciparum, C. parvum, etc.). T. 
gondii main proliferative stage in the mammalian host is the rapidly dividing or 
tachyzoite stage, which is the form used in this study. Sometimes they are described as 
cells because these are unicellular parasites. We now use tachyzoites all the time to 
avoid confusion.9 Scheme 1 illustrates ergosterol biosynthesis for trypanosomatids. 
Farnesyl diphosphate synthase (FPPS) is a key enzyme of the isoprenoid biosynthesis 
that catalyzes the consecutive condensation of isopentenyl diphosphate with 
dimethylallyl diphosphate and with geranyl diphosphate to form farnesyl diphosphate, 
which is the common substrate for enzymes to produce sterols, ubiquinones, dolichols, 
heme a, and prenylated proteins. Farnesyl diphosphate is able to be condensed with an 
additional molecule of isopentenyl diphosphate by the geranylgeranyl diphosphate 











































































































Scheme 1. Ergosterol biosynthesis for trypanosomatids.
On the other hand, Scheme 2 shows the alternate pathway found in Apicomplexan 
parasites to biosynthesize isopentenyl and dimethylallyl diphosphate. It is well-
documented that FPPS is essential for trypanosomatids.22 TgFPPS can be considered a 
key enzyme only under certain circumstances, to be precise, when the isoprenoid 
biosynthesis of the host is inhibited, process known as genetic validation.20 The 
essentiality of FPPS was demonstrated in T. brucei rather than T. cruzi because of the 




































































Scheme 2. The 1-deoxy-D-xylulose-5-phosphate (DOXP) pathway to biosynthesize 
isopentenyl diphosphate and dimethylallyl diphosphate in Apicomplexan parasites.
The recent report of the crystal structure of some complexes of lineal 1,1-
bisphosphonates, developed in our laboratory such as 2-alkylaminoethyl-1,1-
bisphosphonates, with the target enzyme T. cruzi farnesyl diphosphate synthase 
(TcFPPS) provided conclusive data in determining the precise mechanism of action of 
these antiparasitic agents.23 These results, together with previous findings by other 
  
groups24,25 indicated that these compounds behave as competitive inhibitors of the 
substrate by binding to the allylic site of the enzyme, with the phosphonic moieties 
coordinating three magnesium ions at the active site.23 It is worth mentioning that 
predictions of the inhibitors optimal chain length is not straightforward bearing in mind 
that small changes in the number of carbons of the alkyl chain brings about a dramatic 
influence on biological action.26 In addition, FPPS of T. gondii is a bifunctional enzyme 
that catalyzes the condensation of isopentenyl diphosphate with three allylic substrates: 
dimethylallyl diphosphate, geranyl diphosphate, and farnesyl disphosphate.27 
Interestingly, T. gondii FPPS has less than 50% identity of TcFPPS; therefore, it will be 
possible to access extremely selective inhibitors for both enzymes.9 
We were able to develop effective inhibitors against either TcFPPS or TgFPPS.21 
Until now all the FPPSs are homodimeric enzymes that involve Mg2+ or Mn2+ for 
activity.28 TcFPPS is localized to the cytosol.29 
Bisphosphonates (2) are diphosphate (1) analogues in which a substituted 
methylene group replaces the oxygen atom bridge between the two phosphorus atoms of 
the pyrophosphate moiety giving rise to a large family of compounds.30 Several 
bisphosphonates are potent inhibitors of bone resorption and are in clinical use for the 
treatment and prevention of osteoporosis, Paget’s disease, hypercalcemia, tumor bone 
metastases, and other bone diseases.30–32 Aminobisphosphonates became putative 
antiparasitic drugs when these molecules were first found to be effective inhibitors T. 
cruzi proliferation in in vitro and in vivo assays without toxicity to the host cells.33 In 
addition, this behavior was not limited exclusively to T. cruzi but was also observed in 
other trypanosomatids (T. brucei rhodesiense and Leishmania donovani) and 
Apicomplexan parasites, such as T. gondii and P. falciparum34–37, indicating that 
bisphosphonates are promising molecules to control parasitic infections. Selective 
action on bone is based on the binding of the bisphosphonate moiety to the bone 
mineral.30 Interestingly, the acidocalcisomes are equivalent in composition to the bone 
mineral and that accumulation of bisphosphonates in these organelles, as they do in 
bone mineral, aids their antiparasitic activity.4,38–41 The isoprenoid pathway is the target 
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Figure 1. Chemical structures of pyrophosphoric acid, general formula of 
bisphosphonic acids and representative FDA-approved bisphosphonates clinically 
employed for the treatment of different bone disorders.
A relevant achievement of our laboratory was the finding that linear 1,1-
bisphosphonates turned out to be efficient antiparasitic agents43–45 where, in most of 
them, the hydroxyl group at the C-1 position, usually found in those bisphosphonates 
currently employed in the treatment of bone disorders, was absent.42 Compounds 6−9 
were the first examples of linear bisphosphonates that exhibited antiparasitic activity 
against trypanosomatids and Apicomplexan parasites targeting parasitic FPPS.27,43–46 
For example, 6 was a moderate growth inhibitor of intracellular T. cruzi43 and also 
against tachyzoites of T. gondii,27,46 whereas 7 was effective against P. falciparum.27 8 
was practically devoid of activity,44 whereas 9 showed similar cellular activity against 
T. cruzi.45 In addition, -fluoro-1,1-bisphosphonates such as 10 and 11 were neither 
effective against amastigotes of T. cruzi nor the target enzyme TcFPPS; nevertheless, 
they were extremely effective inhibitors of the enzymatic activity of TgFPPS.47 Of 
paramount concern were the 2-alkyl(amino)ethyl-1,1-bisphosphonate derivatives, which 
were potent inhibitors of T. cruzi proliferation targeting TcFPPS with IC50 values in the 
low nanomolar concentrations.48,49 Unquestionable, compounds 12−14 emerge as 
pertinent members of this type of bisphosphonates. For example, 12 was significantly 
more potent than the well-known antiparasitic agent WC-9 against T. cruzi 
(amastigotes),48 under the same assays conditions;50 while 13 was a potent inhibitor of 
the enzymatic activities of TcFPPS.48 Moreover, 14, the bisphosphonate bearing a long 
aliphatic chain, was an effective growth inhibitor of T. cruzi.49 15 was a motivating 
example of a linear bisphosphonate that was designed and synthesized in order to 
optimize structures 12–14. 15 had been designed based on the fact that the presence of 
electron withdrawing group (HO-) at C-1 would enhance the ability to coordinate Mg2+, 
would increase pKa and also by the fact that most bisphosphonates clinically in use have 
this functionality at C-1.51 Unfortunately, 15 is devoid of activity against T. cruzi 
  
growth and TcFPPS, but exhibited a potent and selective inhibition of the enzymatic 
activity towards TgFPPS.51 Linear sulfur-containing bisphosphonates are interesting 
examples of selective anti-Toxoplasma agents as it is the case of 16 and 17.52 Certainly, 
16 is a potent inhibitor of T. gondii proliferation. This cellular activity was associated 
with a potent action against the target enzyme TgFPPS,52 whereas 17 is an unusually 
potent inhibitor towards TgFPPS.52 A strong synergistic effect is observed when the 
sulfur-containing 1,1-bisphosphonate 16 was used in combination with statins against 
the hypervirulent RH strain of T. gondii in in vivo assays.53 Statins, which block the 
mevalonate pathway within the mammalian cells, had exhibited a rather modest 
inhibitory effect against T. gondii cells when tested alone.53 Moreover, the sulfone-
containing derivative 18 exhibited a very potent in vitro activity against T. gondii (ED50 
= 0.1 µM).54 This compound also showed high activity in vivo (ED50 of 0.02 mg/kg) in 
a toxoplasmosis mouse model employing the hypervirulent RH strain of T. gondii.54 It is 
worth mentioning that 18 did not behave as an effective inhibitor of the enzymatic 
activity of TgFPPS (IC50 = 0.27 µM) indicating that TgFPPS was not the primary target 
of this molecule.55 The methylsulfonium derivative 19 has proven to be a moderate 
growth inhibitor against both T. cruzi and T. gondii cells, but a very potent inhibitor of 
the enzymatic activity towards the target enzymes TcFPPS and TgFPPS.52 Finally, -
fluoro-2-alkyl(amino)ethyl derivatives such as 20a20h were unpredictably free of 
cellular activity.55 The structures of these representative compounds are illustrated in 






12, X = NH; Y = H; R = n-hexyl
13, X = NH; Y = H; R = n-heptyl
14, X = NH; Y = H; R = n-dodecyl
15, X = NH; Y = OH; R = n-octyl
16, X = S; Y = H; R = n-heptyl
17, X = S; Y = H; R = n-decyl
18, X = S(O)2; Y = H; R = n-decyl
19, X = S+(CH3); Y = H; R = n-octyl






6, n = 5; R = OH
7, n = 9; R = OH
8, n = 5; R = H
9, n = 4; R = NH2
10, n = 7; R = F
11, n = 8; R = F
20a, R = n-propyl; 20b, R = n-butyl; 20c, R = n-pentyl; 20d, R = n-hexyl;
20e, R = n-heptyl; 20f, R = n-octyl; 20g, R = n-nonyl; 20h, R = n-decyl;
Figure 2. Chemical structures of representative lineal bisphosphonic acids developed in 
our laboratory as putative antiparasitic agents targeting FPPS. 
  
Table 1. Biological activity of bisphosphonates previously prepared in our laboratory 
against T. cruzi (amastigotes), T. gondii (tachyzoites), TcFPPS, and TgFPPS. 
Compound T. cruzi growth 
ED50 (µM) TcFPPS IC50 (µM)
T. gondii growth 
ED50 (µM) TgFPPS IC50 (µM)
10 > 10.0 > 1.0 2.67 0.035
11 > 10.0 > 1.0 > 10.0 0.060
12 0.84 0.49 9.4 0.14
13 10.0 0.058 > 50.0 0.095
14 0.67 0.81 6.23 0.093
15 > 10.0 > 10.0 2.0 0.039
16 > 20.0 > 10.0 0.97 0.069
17 > 20.0 0.097 1.8 0.021
18 NT NT 0.11 0.27
19 >20.0 0.040 7.0 0.013
Rationale
The lack of antiparasitic activity found in the -fluoro-2-alkyl(amino)ethyl 
derivatives was rather unexpected. In fact we further evaluated compounds 20a20h as 
inhibitors of the enzymatic activity against the target enzymes TcFPPS and TgFPPS, 
respectively. 
On the other hand, in order to study the influence of the position of the nitrogen 
atom in our linear 1,1-bisphosphonates, 2-alkylaminomethyl-1,1-bisphosphonates such 
as 21−33 could be considered as very exciting structural variations taking into account 
the selective and potent antiparasitic activity exhibited by 2-alkylaminoethyl-1,1-
bisphosphonates such as 12−14 towards both T. cruzi cells and TcFPPS.23,48,49 Although 
some of the title compounds 21−33 had been previously described as growth inhibitors 
of Entamoeba histolytica and Plasmodium species in in vitro and in vivo studies, there 
were not spectroscopic data available for these compounds.56 Therefore, the influence of 
the position of the nitrogen atom (C-3 versus C-2) seemed to be relevant from the 
pharmacological point of view.
Taking into account that the 2-alkylaminoethyl-1,1-bisphosphonates of type 
1214 were extremely effective growth inhibitors either of T. cruzi cells or of the 
enzymatic activity of the target enzyme TcFPPS,23,48,49 based on the biological activity 
exhibited by the  cyclohexylamine-containing bisphosphonate,48 which showed an IC50 
value of 0.013 µM against TcFPPS but limited biological activity against intracellular T. 
  
cruzi, it was decided to prepare some 1,1-bisphosphonate derivatives bearing a 
cycloalkylamino group in their structure such as 4749. 
Results and discussion
Preparation of the respective 2-alkylaminomethyl-1,1-bisphosphonic acids 
21−33 was successfully carried out according to already published methods.57,58 Thus, 
following a slightly modified published protocol,59 a suitable alkyl or cycloalkyl amine 
treated with triethyl orthoformate and diethyl phosphite at 135 ºC for 2 hours gave rise 
to the corresponding tetraethyl ester derivatives 34−46 in a relatively modest but 
reproducible yields. Then, on treatment with concentrated hydrochloric acid at 100 ºC 
overnight the esters were converted into the title molecules 21−33 in very good yields 
as shown in Scheme 3. 
R = CH2CH2CH3 34, (16%) 21, (73%)
CH2(CH2)2CH3 35, (15%) 22, (100%)
CH2(CH2)3CH3 36, (11%) 23, (70%)
CH2(CH2)4CH3 37, (27%) 24, (81%)
CH2(CH2)5CH3 38, (11%) 25, (100%)
CH2(CH2)6CH3 39, (23%) 26, (97%)
CH2(CH2)7CH3 40, (22%) 27, (82%)
CH2(CH2)8CH3 41, (26%) 28, (100%)
CH2(CH2)9CH3 42, (19%) 29, (100%)
cyclopentyl 43, (28%) 30, (99%)
cyclohexyl 44, (11%) 31, (94%)
cycloheptyl 45, (15%) 32, (83%)















PO3H2100 ºC, 24 h
R
Scheme 3. Synthetic approach for the preparation of 2-alkylaminomethyl-1,1-
bisphosphonic acids.
The 2-cycloalkylaminoethyl-1,1-bisphosphonates 4749 were easily synthesized 
starting from the corresponding cycloalkylamine and the well-known Michael-type 
acceptor 50.60–62 Then, conjugate addition of the cycloalkylamine to form the respective 
tetraethyl esters 4749 with excellent yields followed by hydrolysis by treatment with 
concentrated hydrochlroric acid yielded the desired molecules 4749 as presented in 
Scheme 4. 
R = cyclopentyl 51, (95%) 47, (88%)
cycloheptyl 52, (99%) 48, (73%)














Scheme 4. Synthetic approach for the synthesis of cycloalkyl 2-aminoethyl-1,1-
  
bisphosphonates.
Long chain sulfur-containing 1,1-bisphosphonates such as 5459 were 
synthesized according to our previous results.52 Therefore, the Michael-type acceptor 50 
was treated with undecylmercaptan and dodecylmercaptan to produce the respective 
tetraethyl esters 60 and 61, respectively. On treatment with bromotrimethylsilane in 
methylane chloride, which is the protocol developed by McKenna,63,64 followed by 
digestion with methanol, 60 and 61 were converted into the free bisphosphonic acids 54 
and 57. Sulfur-containing 1,1-bisphosphonate esters are quite sensitive to hydrolysis by 
treatment with concentrated hydrochlroric acid.52 Each compound, in independent 
experiments, was oxidized by treatment with hydrogen peroxide (one equivalent) to 
yield the corresponding sulfoxides 55 and 58, respectively or with two equivalents of 
















































59, (81%) 58, (67%)
60
61
Scheme 5. Synthetic approach for the preparation of long chain sulfur-containing-1,1-
bisphosphonates.
Biological data are shown in Table 2 and 3. As previously mentioned, the -
fluoro-2-alkyl(amino)ethyl derivatives 20a20h resulted to be almost free of 
antiparasitic activity. In spite of not having a significant cellular activity compounds 
20a20h were further evaluated against the main target of the linear bisphosphonates, 
FPPS. All of these fluorine-containing-1,1-bisphosphonates exhibited a potent 
inhibitory action towards the enzymatic activity of either TcFPPS or of TgFPPS. 
Certainly, most of these compounds showed to be nanomolar inhibitors of these key 
enzymes. Long chain derivatives such as 20f and 20g were representative examples of 
potent inhibitors showing IC50 values of 0.085 µM and 0.079 µM against TcFPPS and 
TgFPPS, respectively for 20f and 0.034 µM and 0.051 µM, respectively for 20g. 
Unfortunately, it is difficult to rationalize the lack of cellular activity of this family of 
  
compounds. Evidently, -fluoro-2-alkyl(amino)ethyl-1,1-bisphosphonates do not have 
the appropriate physicochemical parameters to cross two cell membranes (the 
mammalian one and the parasite cell membrane) to reach the target enzyme. Moreover, 
the long chain -fluoro-2-alkyl(amino)ethyl-1,1-bisphosphonates 20f20h were 
cytotoxic molecules making these derivatives of low interest in Medicinal Chemistry. 
This decrease in the antiparasitic activity by making small structural variations on 
nitrogen-containing bisphosphonates such as such 121448,49 to give 1551 has also been 
observed in other bisphosphonates acting on bone mineral affinity targeting the 
mevalonate pathway between -hydroxy- and -fluorobisphosphonates.65
Biological evaluation of 1-alkylaminomethyl-1,1-bisphosphonic acids 2129 
indicated that this structural variation was not beneficial for the biological activity. With 
the exception of compound 28, which resulted to be a fairly modest growth inhibitor of 
intracellular T. cruzi (ED50 5.3 µM), all the title compounds were devoid of cellular 
activity and, for that reasons, they were not further analyzed. 
Unexpectedly, the designed 2-cycloalkyl(amino)ethyl-1,1-bisphosphonates 
4749 were devoid of activity against T. cruzi cells and T. gondii cells. Interestingly, the 
long chain sulfur-containing-1,1-bisphosphonates were effective inhibitors of 
tachyzoites of T. gondii as anticipated according to our previous data in closely related 
sulfur-containing analogues.52–54 All of them 5456, 59 were nanomolar inhibitors of 
tachyzoites of T. gondii being 56 the most effective growth inhibitor with an ED50 value 
of 0.53 µM. In this regard, it is important to note that the reference structure 18 (Figure 
2), which behaved as a potent inhibitor of tachyzoites of T. gondii proliferation (ED50 = 
0.1 µM), did not have TgFPPS as a primary target exhibiting a modest a fairly modest 
inhibitory action towards this target enzyme (IC50 value of 0.8 M).54 Indeed, these long 
chain sulfur-containing -1,1-bisphosphonates will require further efforts to investigate 
their precise mode of action. 
  
Table 2. Biological activity of bisphosphonates against T. cruzi (amastigotes), T. gondii 
(tachyzoites), TcFPPS, TgFPPS, and Vero cells
Compound T. cruzi cells 
ED50 µM








20a > 10.055 0.060 ± 0.03 0.245 ± 0.081 NT
20b > 10.055 > 10.055 0.173 ± 0.04 0.286 ± 0.087 > 20055
20c > 10.055 > 10.055 0.611 ± 0.37 0.299 ± 0.028 NT
20d > 10.055 >10.055 0.915 ± 0.18 0.131 ± 0.017 NT
20e > 10.055 >10.055 0.071 ± 0.02 0.088 ± 0.005 NT
20f > 10.055 4.008 ± 1.19155 0.085 ± 0.03 0.079 ± 0.013 161.755
20g cytotoxic55 2.24 ± 0.31 0.034 ± 0.023 0.051 ± 0.006 15.0
20h cytotoxic55 2.26 ± 0.75 0.136 ± 0.047 0.080 ± 0.004 20.0
Table 3. Biological activity of bisphosphonates against T. cruzi (amastigotes), T. gondii 
(tachyzoites), and Vero cells
Compound T. cruzi cells 
ED50 µM

















47 > 10.0 > 20.0
48 > 10.0 > 20.0
49 > 10.0 > 20.0
54 0.54 ± 0.10
55 0.53 ± 0.096
56 0.38 ± 0.082
59 0.93 ± 0.24
benznidazole 2.58 ± 0.50
a cytotoxic at 10 µM, 5 µM, no inhibition at 2.5 µM
In order to account for the lack of activity of compounds bearing the amino 
group at position 2, Molecular Dynamics (MD) and Quantum Mechanical (QM) 
optimizations were carried out. The protein ligand complex for the compound with the 
  
amino group at position 2 (compound 21) was generated from the crystal structure for 
compound 62 (pdb id 4DXJ). Although no specific interactions between the amino 
groups and the receptor were observed in the 10 ns MD simulations, the side chain is 
fixed in one orientation, directed towards the unsymmetrical magnesium ion (Figure 3). 
A plot for the dihedral angle P-C1-C2-N for 21 and P-C1-N-C3 for 62 (Figure 4) shows 
that this angle remains constant throughout the simulation.
Figure 3. The side chain is fixed in one orientation, directed towards the unsymmetrical 
magnesium ion present at the allylic site of the active site of TcFPPS.
Figure 4. Dihedral angle P-C1-C2-N for 21 (red) and P-C1-N-C3 for 62 (black) 
throughout the MD simulation
  
QM optimizations at the B3LYP/6-311+G(d,p) level were carried out for the 
main conformers of each model compound (63 and 64), simulating the aqueous solvent 
with the polarizable continuum method (PCM). Consistent with previous studies,51 the 
phosphate groups were considered to be doubly protonated, as it is expected for a 
physiological pH of 6.5. We have considered both protonation states for the amino 
group, yielding equivalent conclusions. The molecules were completed by the addition 
of one magnesium atom. The lowest energy conformations (Figure 5) show a strong 
intramolecular hydrogen bond between the phosphate groups for both compounds. 
However, compound 64 shows a weak H-bond between the amino and phosphate 
groups (bond length 2.32 Å and N-H...O angle 120º) while the equivalent H-bond is 
relatively strong for compound 63 (1.77 Å, 151º). The formation of this strong H-bond 
is expected to decrease the conformational entropy in solution, therefore decreasing the 
entropy penalty upon complex formation, and yielding a higher inhibition activity. It is 
worth mentioning that, consistently with our MD and QM studies, ITC measurements23 
found that bisphosphonate compounds bind to the active site due to a combination of a 
favorable entropic driving force and an unfavorable enthalpic energy.
Figure 5. A strong intramolecular hydrogen bond between the phosphate groups for 
both compounds.
In conclusion, the lack of antiparasitic activity shown by the regioisomers of the 
nitrogen-containing bisphosphonates 1214, that is, amino derivatives 2129 provided 
significant insights concerning chemical structure-biological activity relationship. The 
simple moving of the nitrogen atom in representative compounds 1214 had a marked 
  
outcome on the biological activity giving rise to inactive compounds. Efforts in 
optimizing linear bisphosphonates are currently being pursued in our laboratory.
Experimental Section
The glassware used in air- and/or moisture-sensitive reactions was flame-dried and 
reactions were carried out under dry argon. Unless otherwise noted, chemicals were 
commercially available and used without further purification. Solvents were distilled 
before use. Dichloromethane was distilled from phosphorus pentoxide. Nuclear 
magnetic resonance spectra were performed with a Bruker AVANCE NEO 500 or with 
a Bruker Fourier 300 spectrometers. The 1H NMR spectra are referenced with respect to 
the residual CHCl3 proton of the solvent CDCl3 at δ = 7.26 ppm. Coupling constants are 
reported in Hz. 13C NMR spectra were fully decoupled and are referenced to the middle 
peak of the solvent CDCl3 at δ = 77.0 ppm. 31P NMR spectra are referenced with respect 
to the peak of 85% H3PO4 as external reference. For comparative purposes, all NMR 
spectra acquired in D2O for free bisphosphonic acids were recorded at the same 
conditions. Splitting patterns are designated as s, singlet; d, doublet; t, triplet; q, 
quadruplet; dd, double doublet, etc. Melting points were determined with a Fisher–
Johns apparatus and are uncorrected. IR spectra were recorded with a Nicolet Magna 
550 spectrometer. Elemental analyses were performed with an Exeter CE-440 
Elemental Analyzer. Analytical TLC was performed on commercial 0.2 mm aluminum-
coated silica gel plates (F254) and visualized by 254 nm UV or immersion in an aqueous 
solution of (NH4)6Mo7O24·4H2O (0.04 M), Ce(SO4)2 (0.003 M) in concentrated H2SO4 
(10%).
As judged from the homogeneity of the 1H, 13C, 31P NMR spectra and HPLC 
analyses of the title compounds employing a Beckmann Ultrasphere ODS-2 column 5 
M, 250 × 10 mm eluting with water–acetonitrile (9:1) at 3.00 mL/min with a refractive 
index detector indicated a purity >97%.
General procedure for the preparation of tetraethyl 1-n-alkylaminomethyl-1,1-
bisphosphonates
A mixture of the corresponding alkyl or cycloalkyl amine (30 mmol, 4.14 g), triethyl 
orthoformate (30 mmol, 5.0 mL) and diethyl phosphite (60 mmol, 7.7 mL) was heated 
at 135 ºC for 2 h. Then, volatile components were evaporated and the respective 
  
residues were purified by column chromatography (silica gel) eluting with mixtures of 
hexaneacetone giving rise to the desired tetraethyl esters.
General procedure for hydrolysis of tetraethyl 1-n-alkylaminomethyl-1,1-
bisphosphonates
The solvent was evaporated and the residue was treated with a concentrated aqueous 
solution of hydrochloric acid (2 mL). The resulting mixture was heated to reflux for 24 
h. The solvent was evaporated and the residue was crystallized from ethanolwater.
Synthesis of tetraethyl 2-[(alkylthio)ethyl] 1,1-bisphosphonates. General procedure
To a solution of tetraethyl ethenylidenbisphosphonate (50; 300 mg, 1.0 mmol) in 
anhydrous dichloromethane (10 mL) was added triethylamine (1 mmol) and the 
corresponding alkylmercaptan (1 mmol). The reaction mixture was stirred at room 
temperature for 1 h. Water (20 mL) was added, and the mixture was extracted with 
dichloromethane (3  10 mL). The combined organic layers were washed with brine (20 
mL), dried (MgSO4), and the solvent was evaporated.
Synthesis of 2-(alkylthio)ethyl-1,1-bisphosphonic acids. General procedure. A 
solution of the corresponding tetraethyl 2-[(alkylthio)ethyl] 1,1-biphosphonate (1 mmol) 
in anhydrous methylene chloride (10 mL) was treated with trimethylsilyl bromide (10 
equiv.) under an argon atmosphere. The reaction mixture was stirred at room 
temperature for 48 h. Then, methanol (1.0 mL) was added and the solvent was 
evaporated. The residue was dissolved in methanol (8 mL) and the mixture was stirred 
at room temperature for 24 h. The solvent was evaporated and the residue 
redissolved/evaporated in methanol four times, to complete the hydrolysis of remaining 
trimethylsilyl bromide and eliminate the hydrobromic acid created. The residue was 
purified by column chromatography on reverse phase with a mixture of watermethanol 
as eluent and the pure compound was obtained after lyophilization. 
Tetraethyl 1-n-propylaminomethyl-1,1-bisphosphonate (34). Colorless oil; 16% 
yield; 1H NMR (500.13 MHz, CDCl3) δ 0.92 (t, J = 7.4 Hz, 3H, H-5), 1.35 (dt, J = 7.1, 
0.9 Hz, 12H, CH2CH3), 1.49 (sext, J = 7.2 Hz, 2H, H-4), 2.80 (t, J = 7.2 Hz, 2H, H-3), 
3.25 (t, J = 21.7 Hz, 1H, H-1), 4.22 (m, 8H, CH2CH3); 13C NMR (125.77 MHz, CDCl3) 
  
δ 11.5 (C-5), 16.39 (t, J = 3.1 Hz, CH2CH3), 16.44 (t, J = 3.1 Hz, CH2C′H3), 23.1 (C-4), 
52.4 (t, J = 6.0 Hz, C-3), 54.3 (t, J = 145.5 Hz, C-1), 62.8 (t, J = 3.3 Hz, CH2CH3), 63.2 
(t, J = 3.3 Hz, C′H2CH3); 31P NMR (202.46 MHz, CDCl3) δ 19.74 ppm.
Tetraethyl 1-n-butylaminomethyl-1,1-bisphosphonate (35). Colorless oil; 15% yield;  
1H NMR (500.13 MHz, CDCl3) δ 0.90 (t, J = 7.3 Hz, 3H, H-6), 1.35 (dt, J = 7.1, 1.0 Hz, 
12H, CH2CH3), 1.37 (m, J = 7.2 Hz, 2H, H-4), 1.45 (m, J = 7.2 Hz, 2H, H-5), 2.83 (t, J 
= 7.1 Hz, 2H, H-3), 3.24 (t, J = 21.7 Hz, 1H, H-1), 4.21 (m, 8H, CH2CH3); 13C NMR 
(125.77 MHz, CDCl3) δ 13.9 (C-6), 16.4 (t, J = 3.0 Hz, CH2CH3), 16.5 (t, J = 3.1 Hz, 
CH2C′H3), 20.1 (C-5), 32.1 (C-4), 50.3 (t, J = 6.1 Hz, C-3), 54.4 (t, J = 97.4 Hz, C-1), 
62.8 (t, J = 3.4 Hz, CH2CH3), 63.3 (t, J = 3.2 Hz, C′H2CH3); 31P NMR (202.46 MHz, 
CDCl3) δ 19.77 ppm.
Tetraethyl 1-n-pentylaminomethyl-1,1-bisphosphonate (36). Colorless oil; 11% 
yield; 1H NMR (500.13 MHz, CDCl3) δ 0.88 (t, J = 7.0 Hz, 3H, H-7), 1.30 (m, 4H, H-5, 
H-6), 1.35 (dt, J = 7.1, 1.0 Hz, 12H, CH2CH3), 1.47 (m, 2H, H-5), 2.82 (t, J = 7.2 Hz, 
2H, H-3), 3.25 (t, J = 21.8 Hz, 1H, H-1), 4.22 (m, 8H, CH2CH3); 13C NMR (125.77 
MHz, CDCl3) δ 14.0 (C-7), 16.39 (t, J = 3.1 Hz, CH2CH3), 16.44 (t, J = 3.1 Hz, 
CH2C′H3), 22.5 (C-6), 29.1 (C-5), 29.7 (C-4), 50.6 (t, J = 6.0 Hz, C-3), 54.3 (t, J = 
145.4 Hz, C-1), 62.8 (t, J = 3.3 Hz, CH2CH3), 63.2 (t, J = 3.2 Hz, C′H2CH3); 31P NMR 
(202.46 MHz, CDCl3) δ 19.74 ppm.
Tetraethyl 1-n-hexylaminomethyl-1,1-bisphosphonate (37). Colorless oil; 27% yield; 
1H NMR (500.13 MHz, CDCl3) δ 0.88 (t, J = 7.0 Hz, 3H, H-8), 1.30 (m, 6H, H-5, H-6, 
H-7), 1.35 (dt, J = 7.1, 1.1 Hz, 12H, CH2CH3), 1.46 (p, J = 7.3 Hz, 2H, H-4), 2.82 (t, J = 
7.2 Hz, 2H, H-3), 3.25 (t, J = 21.7 Hz, 1H, H-1), 4.22 (m, 8H, CH2CH3); 13C NMR 
(125.77 MHz, CDCl3) δ 14.0 (C-8), 16.42 (t, J = 3.1 Hz, CH2CH3), 16.46 (t, J = 3.0 Hz, 
CH2C′H3), 22.6 (C-7), 26.7 (C-5), 30.0 (C-4), 31.5 (C-6), 50.6 (t, J = 6.0 Hz, C-3), 54.3 
(t, J = 145.4 Hz, C-1), 62.8 (t, J = 3.3 Hz, CH2CH3), 63.2 (t, J = 3.0 Hz, C′H2CH3); 31P 
NMR (202.46 MHz, CDCl3) δ 19.76 ppm.
Tetraethyl 1-n-hepylaminomethyl-1,1-bisphosphonate (38). Colorless oil; 11% yield; 
1H NMR (500.13 MHz, CDCl3) δ 0.86 (t, J = 6.8 Hz, 3H, H-9), 1.26 (m, 8H, H-5, H-6, 
H-7, H-8), 1.33 (t, J = 7.1 Hz, 12H, CH2CH3), 1.44 (p, J = 7.1 Hz, 2H, H-4), 2.80 (t, J = 
  
7.1 Hz, 2H, H-3), 3.23 (t, J = 21.7 Hz, 1H, H-1), 4.22 (m, 8H, CH2CH3); 13C NMR 
(125.77 MHz, CDCl3) δ 14.0 (C-9), 16.40 (t, J = 3.1 Hz, CH2CH3), 16.44 (t, J = 3.0 Hz, 
CH2C′H3), 22.6 (C-8), 27.0 (C-5), 29.1 (C-6), 30.0 (C-4), 31.8 (C-7), 50.6 (t, J = 6.0 Hz, 
C-3), 54.3 (t, J = 145.4 Hz, C-1), 62.8 (t, J = 3.2 Hz, CH2CH3), 63.2 (t, J = 3.2 Hz, 
C′H2CH3); 31P NMR (202.46 MHz, CDCl3) δ 19.74 ppm.
Tetraethyl 1-n-octylaminomethyl-1,1-bisphosphonate (39). Colorless oil; 23% yield; 
1H NMR (500.13 MHz, CDCl3) δ 0.88 (t, J = 7.0 Hz, 3H, H-10), 1.26 (m, 10H, -CH2-), 
1.35 (t, J = 7.1 Hz, 12H, CH2CH3), 1.46 (p, J = 7.21 Hz, 2H, H-4), 2.82 (dt, J = 7.1, 1.1 
Hz, 2H, H-3), 3.24 (t, J = 21.7 Hz, 1H, H-1), 4.21 (m, 8H, CH2CH3); 13C NMR (125.77 
MHz, CDCl3) δ 14.1 (C-10), 16.4 (t, J = 3.1 Hz, CH2CH3), 16.5 (t, J = 3.0 Hz, 
CH2C′H3), 22.6 (C-9), 27.0 (C-5), 29.2 (C-6), 29.4 (C-7), 30.0 (C-4), 31.8 (C-8), 50.6 (t, 
J = 6.0 Hz, C-3), 54.4 (t, J = 145.4 Hz, C-1), 62.8 (t, J = 3.3 Hz, CH2CH3), 63.2 (t, J = 
3.2 Hz, C′H2CH3); 31P NMR (202.46 MHz, CDCl3) δ 19.76 ppm.
Tetraethyl 1-n-nonylaminomethyl-1,1-bisphosphonate (40). Colorless oil; 22% 
yield; 1H NMR (500.13 MHz, CDCl3) δ 0.88 (t, J = 7.0 Hz, 3H, H-11), 1.25 (m, 12H, -
CH2-), 1.35 (dt, J = 7.0, 1.0 Hz, 12H, CH2CH3), 1.45 (p, J = 7.2 Hz, 2H, H-4), 2.81 (t, J 
= 7.2, 1.1 Hz, 2H, H-3), 3.25 (t, J = 21.7 Hz, 1H, H-1), 4.20 (m, 8H, CH2CH3); 13C 
NMR (125.77 MHz, CDCl3) δ 14.0 (C-11), 16.37 (t, J = 3.1 Hz, CH2CH3), 16.42 (t, J = 
3.1 Hz, CH2C′H3), 22.6 (C-10), 27.0 (C-5), 29.2 (C-6), 29.4 (C-7), 29.4 (C-8), 30.0 (C-
4), 31.8 (C-9), 50.8 (t, J = 5.7 Hz, C-3), 54.3 (t, J = 145.4 Hz, C-1), 62.8 (t, J = 3.3 Hz, 
CH2CH3), 63.2 (t, J = 2.9 Hz, C′H2CH3); 31P NMR (202.46 MHz, CDCl3) δ 19.73 ppm.
Tetraethyl 1-n-decylaminomethyl-1,1-bisphosphonate (41). Colorless oil; 26% yield; 
1H NMR (500.13 MHz, CDCl3) δ 0.86 (t, J = 6.8 Hz, 3H, H-12), 1.26 (m, 14H, -CH2-), 
1.33 (t, J = 6.7 Hz, 12H, CH2CH3), 1.43 (p, J = 7.2 Hz, 2H, H-4), 2.79 (t, J = 7.0, 1.1 
Hz, 2H, H-3), 3.23 (t, J = 21.7 Hz, 1H, H-1), 4.19 (m, 8H, CH2CH3); 13C NMR (125.77 
MHz, CDCl3) δ 14.1 (C-12), 16.39 (t, J = 3.0 Hz, CH2CH3), 16.44 (t, J = 3.1 Hz, 
CH2C′H3), 22.6 (C-11), 27.0 (C-5), 29.3 (C-6), 29.4 (C-7), 29.5 (C-8), 29.6 (C-9), 30.0 
(C-4), 31.8 (C-10), 50.6 (t, J = 6.0 Hz, C-3), 54.3 (t, J = 145.4 Hz, C-1), 62.8 (t, J = 3.3 
Hz, CH2CH3), 63.2 (t, J = 3.0 Hz, C′H2CH3); 31P NMR (202.46 MHz, CDCl3) δ 19.74 
ppm.
  
Tetraethyl 1-n-Undecylaminomethyl-1,1-bisphosphonate (42). Colorless oil; 19% 
yield; 1H NMR (500.13 MHz, CDCl3) δ 0.86 (t, J = 6.8 Hz, 3H, H-13), 1.23 (m, 16H, -
CH2-), 1.33 (t, J = 6.7 Hz, 12H, CH2CH3), 1.43 (p, J = 7.2 Hz, 2H, H-4), 2.79 (t, J = 7.0 
Hz, 2H, H-3), 3.22 (t, J = 21.7 Hz, 1H, H-1), 4.19 (m, 8H, CH2CH3); 13C NMR (125.77 
MHz, CDCl3) δ 14.1 (C-13), 16.39 (t, J = 3.0 Hz, CH2CH3), 16.44 (t, J = 3.1 Hz, 
CH2C′H3), 22.6 (C-12), 27.0 (C-5), 29.3 (C-6), 29.47 (C-7), 29.57 (C-8), 29.59 (C-9, C-
10), 30.0 (C-4), 31.9 (C-11), 50.6 (t, J = 6.1 Hz, C-3), 54.3 (t, J = 145.6 Hz, C-1), 62.8 
(t, J = 3.3 Hz, CH2CH3), 63.3 (t, J = 3.2 Hz, C′H2CH3); 31P NMR (202.46 MHz, CDCl3) 
δ 19.75 ppm.
Tetraethyl (Cyclopentylamino)methyl-1,1-bisphosphonate (43). Colorless oil; 28% 
yield; 1H NMR (500.13 MHz, CDCl3) δ 1.35 (dt, J = 7.1, 1.6 Hz, 12H, CH2CH3), 1.52 
(m, 4H, -CH2-), 1.72 (m, 4H, -CH2-), 3.32 (t, J = 22.0 Hz, 1H, H-1), 3.48 (t, J = 5.8 Hz, 
2H, H-3), 4.19 (m, 8H, CH2CH3); 13C NMR (125.77 MHz, CDCl3) δ 16.4 (t, J = 3.1 Hz, 
CH2CH3), 16.5 (t, J = 3.1 Hz, CH2C′H3), 23.9 (C-5), 32.8 (C-4), 52.6 (t, J = 145.4 Hz, 
C-1), 59.2 (t, J = 5.9 Hz, C-3), 62.8 (t, J = 3.4 Hz, CH2CH3), 63.4 (t, J = 3.4 Hz, 
C′H2CH3); 31P NMR (202.46 MHz, CDCl3) δ 19.93 ppm.
Tetraethyl (Cyclohexylamino)methyl-1,1-bisphosphonate (44). Colorless oil; 11% 
yield; 1H NMR (500.13 MHz, CDCl3) δ 1.061.25 (m, 5H, -CH2-), 1.35 (dt, J = 7.1, 1.3 
Hz, 12H, CH2CH3), 1.49 (m, 1H, -CH2-), 1.59 (m, 1H, -CH2-), 1.72 (m, 2H, -CH2-), 
1.83 (m, 3H, -CH2-), 2.76 (tt, J = 9.9, 3.7 Hz, 2H, H-3), 3.42 (t, J = 22.0 Hz, 1H, H-1), 
4.19 (m, 8H, CH2CH3); 13C NMR (125.77 MHz, CDCl3) δ 16.4 (t, J = 3.1 Hz, CH2CH3), 
16.5 (t, J = 2.9 Hz, CH2C′H3), 24.7 (C-5), 26.0 (C-6), 33.1 (C-4), 51.0 (t, J = 145.4 Hz, 
C-1), 56.2 (t, J = 5.8 Hz, C-3), 62.8 (t, J = 3.3 Hz, CH2CH3), 63.3 (t, J = 3.2 Hz, 
C′H2CH3); 31P NMR (202.46 MHz, CDCl3) δ 19.94 ppm.
Tetraethyl (Cycloheptylamino)methyl-1,1-bisphosphonate (45). Colorless oil; 15% 
yield; 1H NMR (500.13 MHz, CDCl3) δ 1.34 (dt, J = 7.1, 1.2 Hz, 12H, CH2CH3), 1.39 
(m, 2H, -CH2-), 1.52 (m, 4H, -CH2-), 1.64 (m, 2H, -CH2-), 1.78 (m, 4H, -CH2-), 2.98 (p, 
J = 4.1 Hz, 2H, H-3), 3.36 (t, J = 22.1 Hz, 1H, H-1), 4.21 (m, 8H, CH2CH3); 13C NMR 
(125.77 MHz, CDCl3) δ 16.4 (t, J = 2.9 Hz, CH2CH3), 16.5 (t, J = 3.3 Hz, CH2C′H3), 
24.0 (C-5), 28.4 (C-6), 34.3 (C-4), 51.7 (t, J = 145.3 Hz, C-1), 58.4 (t, J = 5.7 Hz, C-3), 
  
62.7 (t, J = 3.3 Hz, CH2CH3), 63.4 (t, J = 3.2 Hz, C′H2CH3); 31P NMR (202.46 MHz, 
CDCl3) δ 19.99 ppm.
Tetraethyl (Piperidin-1-yl)methyl-1,1-bisphosphonate (46). Colorless oil; 37% yield; 
1H NMR (500.13 MHz, CDCl3) δ 1.35 (dt, J = 7.1, 1.2 Hz, 12H, CH2CH3), 1.42 (m, 2H, 
-CH2-), 1.54 (p, J = 5.4 Hz, 4H, -CH2-), 1.64 (m, 2H, -CH2-), 1.78 (m, 4H, -CH2-), 2.96 
(m, 4H, H-3), 3.34 (t, J = 25.0 Hz, 1H, H-1), 4.20 (m, 8H, CH2CH3); 13C NMR (125.77 
MHz, CDCl3) δ 16.4 (t, J = 2.9 Hz, CH2CH3), 16.5 (t, J = 3.1 Hz, CH2C′H3), 23.9 (C-5), 
26.8 (C-4), 53.0 (t, J = 4.5 Hz, C-3), 62.4 (t, J = 140.8 Hz, C-1), 62.7 (t, J = 3.3 Hz, 
CH2CH3), 63.4 (t, J = 3.2 Hz, C′H2CH3); 31P NMR (202.46 MHz, CDCl3) δ 18.56 ppm.
Tetraethyl 1-[(Cyclopentylamino)ethyl] 1,1-bisphosphonate (51). Colorless oil; 95% 
yield; 1H NMR (500.13 MHz, CDCl3) δ 1.32 (t, J = 7.1 Hz, 12H, CH2CH3), 1.36 (m, 
1H, -CH2-), 1.51 (m, 2H, -CH2-), 1.66 (m, 2H, -CH2-), 1.80 (m, 2H, -CH2-), 2.70 (tt, J = 
23.5, 5.7 Hz, 1H, H-1), 3.12 (dt, J = 16.7, 6.0 Hz, 2H, H-2), 3.06 (q, J = 6.9 Hz, 1H, H-
4), 4.16 (m, 8H, CH2CH3); 13C NMR (125.77 MHz, CDCl3) δ 16.3 (t, J = 3.2 Hz, 
CH2CH3), 16.4 (t, J = 3.1 Hz, CH2C′H3), 24.0 (C-5), 32.6 (C-4), 37.2 (t, J = 132.9 Hz, 
C-1), 44.2 (t, J = 4.2 Hz, C-2), 58.9 (C-4), 62.5 (t, J = 6.8 Hz, CH2CH3), 62.8 (t, J = 6.8 
Hz, C′H2CH3); 31P NMR (202.46 MHz, CDCl3) δ 22.60 ppm.
Tetraethyl 1-[(Cycloheptylamino)ethyl] 1,1-bisphosphonate (52). Colorless oil; 99% 
yield; 1H NMR (500.13 MHz, CDCl3) δ 1.35 (t, J = 7.1 Hz, 12H, CH2CH3), 2.63 (tt, J = 
23.6, 5.8 Hz, 1H, H-1), 3.15 (dt, J = 16.7, 5.9 Hz, 2H, H-2), 4.18 (m, 8H, CH2CH3); 13C 
NMR (125.77 MHz, CDCl3) δ 16.39 (t, J = 2.9 Hz, CH2CH3), 16.43 (t, J = 3.1 Hz, 
CH2C′H3), 24.3 (C-6), 28.3 (C-7), 34.5 (C-5), 37.4 (t, J = 132.2 Hz, C-1), 43.2 (t, J = 
4.3 Hz, C-2), 57.9 (C-4), 62.5 (t, J = 6.6 Hz, CH2CH3), 62.8 (t, J = 6.8 Hz, C′H2CH3); 
31P NMR (202.46 MHz, CDCl3) δ 22.87 ppm. 
Tetraethyl  1-[(4-methylcyclohexylamino)ethyl] 1,1-bisphosphonic acid (53). 
Colorless oil, 94% yield; 1H NMR (500.13 MHz, CDCl3) δ 0.87, 0.90 (d, J = 6.5 Hz, 3H 
CH3), 1.342, 1.347 (t, J = 7.0 Hz, 12H, CH2CH3), 2.63 (tt, J = 22.9, 5.6 Hz, 1H, H-1), 
3.15, 3.19 (dt, J = 16.5, 5.6 Hz, 2H, H-2), 4.19 (m, 8H, CH2CH3); 31P NMR (202.46 
MHz, CDCl3) δ 22.78, 22.90 ppm.
  
1-n-Propylaminomethyl-1,1-bisphosphonic acid (21). White solid, 73% yield; mp 
207 ºC; 1H NMR (500.13 MHz, D2O) δ 0.91 (t, J = 7.5 Hz, 3H, H-5), 1.64 (sext, J = 7.5 
Hz, 2H, H-4), 2.90 (t, J = 16.4 Hz, 1H, H-1), 3.22 (t, J = 7.5 Hz, 2H, H-3); 13C NMR 
(125.77 MHz, D2O) δ 10.1 (C-5), 19.8 (C-4), 51.1 (t, J = 2.8 Hz, C-3), 58.3 (t, J = 115.8 
Hz, C-1); 31P NMR (202.46 MHz, D2O) δ 8.40 ppm. HRMS (ESI) calcd. for 
(C4H13O6NP2Na) [M+Na]+ 256.0110; found 256.0110. Anal. calcd. for 
(C4H13O6NP2.½H2O): C, 19.84; H, 5.83; N, 5.79. Found C, 19.34; H, 6.08; N, 5.62. 
1-n-Butylaminomethyl-1,1-bisphosphonic acid (22). White solid; 100% yield; mp 
215 ºC; 1H NMR (500.13 MHz, D2O) δ 0.85 (t, J = 7.4 Hz, 3H, H-6), 1.32 (sext, J = 7.5 
Hz, 2H, H-5), 1.61 (q, J = 7.6 Hz, 2H, H-4), 2.90 (t, J = 16.4 Hz, 1H, H-1), 3.25 (t, J = 
7.5 Hz, 2H, H-3); 13C NMR (125.77 MHz, D2O) δ 12.9 (C-6), 19.0 (C-5), 28.3 (C-4), 
49.5 (t, J = 2.9 Hz, C-3), 58.4 (t, J = 115.2 Hz, C-1); 31P NMR (202.46 MHz, D2O) δ 
8.39 ppm. HRMS (ESI) calcd. for (C5H15O6NP2Na) [M + Na]+ 270.0267; found 
270.0262. Anal. calcd. for (C5H15O6NP2): C, 24.30; H, 6.12; N, 5.67. Found C, 24.69; H, 
6.60; N, 5.39. 
1-n-Pentylaminomethyl-1,1-bisphosphonic acid (23). white solid; 70% yield; mp = 
201 ºC; 1H NMR (500.13 MHz, D2O) δ 0.79 (t, J = 7.1 Hz, 3H, H-7), 1.25 (m, 4H, H-5, 
H-6), 1.62 (q, J = 7.5 Hz, 2H, H-4), 2.88 (t, J = 16.3 Hz, 1H, H-1), 3.24 (t, J = 7.8 Hz, 
2H, H-3); 13C NMR (125.77 MHz, D2O) δ 13.1 (C-7), 21.6 (C-6), 26.0 (C-5), 27.7 (C-
4), 49.8 (t, J = 2.6 Hz, C-3), 58.5 (t, J = 115.4 Hz, C-1); 31P NMR (202.46 MHz, D2O) δ 
8.45 ppm. HRMS (ESI) calcd. for (C6H18O6NP2) [M+H]+ 262.0604; found 262.0606.
1-n-Hexylaminomethyl-1,1-bisphosphonic acid (24). White solid, 81% yield; mp = 
210 ºC; 1H NMR (500.13 MHz, D2O) δ 0.77 (t, J = 7.1 Hz, 3H, H-8), 1.23 (m, 4H, H-6, 
H-7), 1.31 (m, 2H, H-5), 1.61 (q, J = 7.6 Hz, 2H, H-4), 2.87 (t, J = 16.3 Hz, 1H, H-1), 
3.23 (t, J = 7.6 Hz, 2H, H-3); 13C NMR (125.77 MHz, D2O) δ 13.3 (C-8), 21.7 (C-7), 
25.2 (C-5), 26.3 (C-4), 30.3 (C-6), 49.8 (t, J = 3.2 Hz, C-3), 58.5 (t, J = 116.3 Hz, C-1); 
31P NMR (202.46 MHz, D2O) δ 8.46 ppm.  HRMS (ESI) calcd. for (C7H20O6NP2) [M + 
H]+ 276.0760; found 277.0767. Anal. calcd. for (C7H19O6NP2): C, 30.55; H, 6.96; N, 
5.09. Found C, 30.17; H, 7.06; N, 4.97. 
  
1-n-Heptylaminomethyl-1,1-bisphosphonic acid (25). White solid; mp 198 ºC. 1H 
NMR (500.13 MHz, D2O) δ 0.78 (t, J = 6.9 Hz, 3H, H-9), 1.21 (m, 4H, H-7, H-8), 1.29 
(m, 2H, H-5, H-6), 1.63 (p, J = 7.7 Hz, 2H, H-4), 2.90 (t, J = 16.4 Hz, 1H, H-1), 3.25 (t, 
J = 7.6 Hz, 2H, H-3); 13C NMR (125.77 MHz, D2O) δ 13.3 (C-9), 21.9 (C-8), 25.5 (C-
5), 26.3 (C-4), 28.0 (C-6), 30.8 (C-7), 49.8 (t, J = 3.1 Hz, C-3), 58.4 (t, J = 116.0 Hz, C-
1); 31P NMR (202.46 MHz, D2O) δ 8.36 ppm. HRMS (ESI) calcd. for (C8H21O6NP2Na) 
[M + Na]+ 312.0736; found 312.0735. Anal. calcd. for (C8H21O6NP2): C, 33.22; H, 7.32; 
N, 4.84. Found C, 33.65; H, 7.01; N, 5.11. 
1-n-Octylaminomethyl-1,1-bisphosphonic acid (26). White solid; 97% yield; mp = 
201 ºC. 1H NMR (500.13 MHz, D2O) δ 0.75 (m, 3H, H-10), 1.17 (m, 6H, -CH2-), 1.28 
(m, 4H, -CH2-), 1.61 (m, 2H, H-4), 2.87 (t, J = 16.2 Hz, 1H, H-1), 3.22 (t, J = 7.0 Hz, 
2H, H-3); 13C NMR (125.77 MHz, D2O) δ 13.4 (C-10), 22.0 (C-9), 25.6 (C-5), 26.3 (C-
4), 28.1 (C-6), 28.2 (C-8), 31.0 (C-7), 49.8 (t, J = 2.8 Hz, C-3), 58.5 (t, J = 115.5 Hz, C-
1); 31P NMR (202.46 MHz, D2O) δ 8.51 ppm. HRMS (ESI) calcd. for (C9H23O6NP2Na) 
[M+Na]+ 326.0893; found 326.0850. Anal. calcd. for (C9H23O6NP2): C, 35.65; H, 7.65; 
N, 4.62. Found C, 35.48; H, 8.01; N, 3.86. 
1-n-Nonylaminomethyl-1,1-bisphosphonic acid (27). White solid; 82% yield; mp = 
195 ºC. 1H NMR (500.13 MHz, D2O) δ 0.77 (t, J = 6.8 Hz, 3H, H-11), 1.20 (m, 8H, -
CH2-), 1.28 (m, 4H, -CH2-), 1.64 (p, J = 7.5 Hz, 2H, H-4), 3.00 (t, J = 16.3 Hz, 1H, H-
1), 3.25 (t, J = 7.6 Hz, 2H, H-3); 13C NMR (125.77 MHz, D2O) δ 13.4 (C-11), 22.0 (C-
10), 25.6 (C-5), 26.2 (C-4), 28.26 (C-6), 28.31 (C-9), 28.4 (C-8), 31.1 (C-7), 49.7 (t, J = 
3.1 Hz, C-3), 57.0 (t, J = 113.3 Hz, C-1); 31P NMR (202.46 MHz, D2O) δ 8.34 ppm. 
HRMS (ESI) calcd. for (C10H26O6NP2) [M+H]+ 318.1230; found 318.1220. Anal. calcd. 
for (C10H25O6NP2): C, 37.85; H, 7.94; N, 4.41. Found C, 37.82; H, 8.07; N, 4.44. 
1-n-Decylaminomethyl-1,1-bisphosphonic acid (28). White solid; 100% yield; mp = 
197 ºC; 1H NMR (500.13 MHz, D2O) δ 0.76 (t, J = 6.9 Hz, 3H, H-12), 1.18 (m, 10H, -
CH2-), 1.28 (m, 4H, -CH2-), 1.62 (p, J = 7.4 Hz, 2H, H-4), 2.88 (t, J = 16.8 Hz, 1H, H-
1), 3.23 (t, J = 7.6 Hz, 2H, H-3); 13C NMR (125.77 MHz, D2O) δ 13.4 (C-12), 22.0 (C-
11), 25.6 (C-5), 26.4 (C-4), 28.26 (C-6), 28.41 (C-10), 28.45 (C-9), 28.6 (C-8), 31.1 (C-
7), 49.9 (t, J = 2.9 Hz, C-3), 58.5 (t, J = 115.6 Hz, C-1); 31P NMR (202.46 MHz, D2O) δ 
8.44 ppm. HRMS (ESI) calcd. for (C11H27O6NP2Na) [M+Na]+ 354.1206; found 
  
354.1208. Anal. calcd. for (C11H27O6NP2): C, 39.88; H, 8.21; N, 4.23. Found C, 39.51; 
H, 8.01; N, 3.98. 
1-n-Undecylaminomethyl-1,1-bisphosphonic acid (29). White solid; 100% yield; mp 
= 203 ºC; 1H NMR (500.13 MHz, D2O) δ 0.77 (m, 3H, H-13), 1.19 (m, 16H, -CH2-), 
1.64 (m, 2H, H-4), 3.11 (t, J = 15.7 Hz, 1H, H-1), 3.25 (m, 2H, H-3); 13C NMR (125.77 
MHz, D2O) δ 13.4 (C-13), 22.0 (C-12), 25.6 (C-5), 26.1 (C-4), 28.25 (C-6), 28.46 (C-
10, C-11), 28.6 (C-9), 28.7 (C-8), 31.2 (C-7), 49.5 (t, J = 3.3 Hz, C-3), 55.5 (t, J = 111.8 
Hz, C-1); 31P NMR (202.46 MHz, D2O) δ 8.33 ppm. HRMS (ESI) calcd. for 
(C12H29O6NP2Na) [M+Na]+ 368.1362; found 368.1361. Anal. calcd. for (C12H29O6NP2): 
C, 41.74; H, 8.46; N, 4.06. Found C, 41.21; H, 8.32; N, 3.93. 
(Cyclopentylamino)methyl-1,1-bisphosphonic acid (30). White solid; 99% yield; mp 
210 ºC; 1H NMR (500.13 MHz, CDCl3) δ 1.62 (m, 6H, H4a, H-5), 2.05 (m, 2H, H-4b), 
3.43 (t, J = 18.1 Hz, 1H, H-1), 3.98 (p, J = 7.2 Hz, 1H, H-3); 13C NMR (125.77 MHz, 
CDCl3) δ 23.6 (C-5), 29.2 (C-4), 54.0 (t, J = 124.3 Hz, C-1), 61.3 (t, J = 3.2 Hz, C-3); 
31P NMR (202.46 MHz, D2O) δ 8.02 ppm. HRMS (ESI) calcd. for C6H16NO6P2 [M + 
H]+ 260.0447; found 260.0454. Anal. calcd. for (C6H15O6NP2): C, 27.81; H, 5.83; N, 
5.41. Found C, 28.17; H, 5.72; N, 5.08.
(Cyclohexylamino)methyl-1,1-bisphosphonic acid (31). white solid; 94% yield; mp 
213 ºC; 1H NMR (500.13 MHz, D2O) δ 1.14 (m, 2H, H-6ax.), 1.28 (sext, J = 11.5 Hz, 
4H, H-5), 1.54 (m, 2H, H-6eq.), 1.71 (m, 2H, H-4ax.), 2.04 (m, 2H, H-4eq.), 3.06 (t, J = 
16.2 Hz, 1H, H-1), 3.46 (m, 1H, H-3); 13C NMR (125.77 MHz, CDCl3) δ 23.7 (C-6), 
24.6 (C-5), 29.5 (C-4), 54.9 (t, J = 124.3 Hz, C-1), 57.9 (C-3); 31P NMR (202.46 MHz, 
D2O) δ 8.72 ppm. HRMS (ESI) calcd. for C7H18NO6P2 [M + H]+ 274.0604; found 
274.0606. Anal. calcd. for (C7H17O6NP2): C, 30.78; H, 6.27; N, 5.13. Found C, 30.43; 
H, 6.18; N, 4.99.
(Cycloheptylamino)methyl-1,1-bisphosphonic acid (32). White solid; 83% yield; mp 
225 ºC; 1H NMR (500.13 MHz, D2O) δ 1.47 (m, 6H, -CH2-), 1.62 (m, 6H, -CH2-), 2.04 
(p, J = 6.5 Hz, 2H, H-5b), 3.12 (t, J = 16.3 Hz, 1H, H-1), 3.62 (sept, J = 4.4 Hz, 1H, H-
3); 13C NMR (125.77 MHz, D2O) δ 23.1 (C-6), 27.4 (C-5), 30.8 (C-4), 54.4 (t, J = 112.4 
Hz, C-1), 61.0 (t, J = 3.1 Hz, C-3); 31P NMR (202.46 MHz, D2O) δ 8.74 ppm. HRMS 
  
(ESI) calcd. for C8H20NO6P2 [M+H]+ 288.0760; found 288.0758. Anal. calcd. for 
(C8H19O6NP2): C, 33.46; H, 6.67; N, 4.88. Found C, 33.70; H, 6.58; N, 4.65.
(Piperidin-1-yl)methyl-1,1-bisphosphonic acid (33). White solid; 82% yield; mp 238 
ºC; 1H NMR (500.13 MHz, D2O) δ 1.69 (m, 2H, H-5), 1.87 (m, 4H, H-4), 3.15 (t, J = 
17.6 Hz, 1H, H-1), 3.52 (m, 4H, H-3); 13C NMR (125.77 MHz, D2O) δ 21.0 (C-5), 24.3 
(C-4), 53.8 (C-3), 63.8 (t, J = 106.8 Hz, C-1); 31P NMR (202.46 MHz, D2O) δ 6.77 
ppm.  HRMS (ESI) calcd. for C6H15NO6P2Na [M+Na]+ 282.0267; found 282.0258. 
Anal. calcd. for (C6H15O6NP2): C, 27.81; H, 5.83; N, 5.41. Found C, 27.44; H, 5.58; N, 
5.06.
1-[(Cyclopentylamino)ethyl] 1,1-bisphosphonic acid (47). White solid; 88% yield; 
mp 228 ºC; 1H NMR (500.13 MHz, D2O) δ 1.62 (m, 6H, H-5a, H-6), 1.95 (m, 2H, H-
5b), 2.39 (tt, J = 21.5, 7.3 Hz, 1H, H-1), 3.35 (dt, J = 14.3, 7.3 Hz, 2H, H-2), 3.55 (m. 
1H, H-4); 13C NMR (125.77 MHz, D2O) δ 23.4 (C-6), 29.4 (C-5), 36.3 (t, J = 120.9 Hz, 
C-1), 43.6 (t, J = 2.4 Hz, C-2), 59.5 (C-4); 31P NMR (202.46 MHz, D2O) δ 15.58 ppm. 
HRMS (ESI) calcd. for C7H18O6NP2 [M+H]+ 274.0604; found 274.0610.
1-[(Cycloheptylamino)ethyl] 1,1-bisphosphonic acid (48). 73% yield; white solid;  
mp 220 ºC; 1H NMR (500.13 MHz, D2O) δ 1.45 (m, 6H, H-6a, H-7), 1.60 (m, 4H, H-5a, 
H-6b), 1.97 (m, 2H, H-5b), 2.37 (tt, J = 21.4, 7.3 Hz, 1H, H-1), 3.28 (hept, J = 4.4 Hz, 
1H, H-4), 3.36 (dt, J = 14.3, 7.3 Hz, 2H, H-2); 13C NMR (125.77 MHz, D2O) δ 23.0 (C-
7), 27.3 (C-6), 30.6 (C-5), 36.2 (t, J = 120.8 Hz, C-1), 42.3 (t, J = 2.3 Hz, C-2), 59.4 (C-
4); 31P NMR (202.46 MHz, D2O) δ 15.59 ppm. HRMS (ESI) calcd. for C9H22O6NP2 
[M+H]+ 302.0917; found 302.0905.
1-[(4-methylcyclohexylamino)ethyl] 1,1-bisphosphonic acid (49). 76% yield; white 
solid; mp = 175 ºC; 1H NMR (125.77 MHz, D2O) δ 0.80 (d, J = 6.6 Hz, 6H, CH(CH3)2), 
0.84 (d, J = 6.6 Hz, 6H, CH(CH′3)2), 2.41 (tt, J = 21.4, 7.3 Hz, 1H, H-1), 3.25 (m. 1H, 
H-4), 3.36 (dt, J = 14.0, 7.1 Hz, 2H, H-2); 13C NMR (125.77 MHz, D2O) δ 19.9 21.0 
(CH3), 25.4 (C-5), 28.4 28.9 (C-5), 30.9 32.2 (C-6), 36.1 (t, J = 121.1 Hz, C-1), 36.2 (t, 
J = 120.8 Hz, C-1), 42.0 (t, J = 2.2 Hz, C-2), 42.5 (t, J = 2.6 Hz, C-2), 55.5 57.1 (C-4); 
31P NMR (202.46 MHz, D2O) δ 15.59 ppm. HRMS (ESI) calcd. for C9H22O6NP2 
[M+H]+ 302.0917; found 302.0931.
  
Tetraethyl 1-[(n-Undec-1-ylthio)ethyl]-1,1-bisphosphonate (60). 74% yield, colorless 
oil; 1H NMR (500.13 MHz, CDCl3)  0.88 (t, J = 7.0 Hz, 3H, H-14), 1.26 (m,16H, -
CH2-), 1.35 (t, J = 7.1 Hz, 12H, CH2CH3), 1.59 (p, J = 7.3 Hz, 2H, H-5), 2.56 (t, J = 7.4 
Hz, 2H, H-4), 2.59 (tt, J = 23.6, 6.0 Hz, 1H, H-1), 3.04 (dt, J = 16.3, 5.9 Hz, 2H, H-2), 
4.21 (m, 8H, CH2CH3); 13C NMR (125.77 MHz, CDCl3)  14.1 (C-14), 16.3 (d, J = 6.4 
Hz, CH2CH3), 22.6 (C-13), 27.7 (t, J = 5.2 Hz, C-2), 28.8 (C-12), 29.2 (C-11), 29.3 (C-
10), 29.4 (C-9), 29.47 (C-8), 29.53 (C-6, C-7), 31.8 (C-5), 33.1 (C-4), 39.0 (t, J = 131.4 
Hz, C-1), 62.8 (dd, J = 18.8, 6.8 Hz, CH2CH3); 31P NMR (202.46 MHz, CDCl3)  
21.75.
Tetraethyl 1-[(n-Dodec-1-ylthio)ethyl]-1,1-bisphosphonate (61). Colorless oil; 55% 
yield; 1H NMR (500.13 MHz, CDCl3)  0.88 (t, J = 7.0 Hz, 3H, H-15), 1.26 (m,16H, -
CH2-), 1.35 (t, J = 7.1 Hz,12H, CH2CH3), 1.59 (p, J = 7.5 Hz, 2H, H-5), 2.56 (t, J = 7.5 
Hz, 2H, H-4), 2.59 (tt, J = 23.9, 5.9 Hz, 1H, H-1), 3.04 (dt, J = 16.3, 5.9 Hz, 2H, H-2), 
4.21 (m, 8H, CH2CH3); 13C NMR (125.77 MHz, CDCl3)  14.1 (C-15), 16.4 (d, J = 6.3 
Hz, CH2CH3), 22.7 (C-14), 27.7 (t, J = 4.9 Hz, C-2), 28.9 (C-13), 29.2 (C-12), 29.3 C-
11), 29.4 (C-10), 29.51 (C-9), 29.57 (C-8), 29.59 (C-7), 29.62 (C-6), 31.9 (C-5), 33.1 
(C-4), 39.1 (t, J = 131.4 Hz, C-1), 62.8 (dd, J = 18.7, 6.6 Hz, CH2CH3); 31P NMR 
(202.46 MHz, CDCl3)  21.76.
1-[(n-Undecylthio)ethyl]-1,1-bisphosphonic acid (54). 45% yield; white solid; mp = 
95 ºC; 1H NMR (500.13 MHz, DMSO-d6) δ 0.84 (t, J = 6.9 Hz, 3H, H-14), 1.23 (m, 
14H, -CH2-), 1.31 (m, 2H, H-6), 1.49 (p, J = 7.3 Hz, 2H, H-5), 2.10 (tt, J = 22.5, 6.0 Hz, 
1H, H-1), 2.84 (t, J =15.5, 6.1 Hz, 2H, H-2); 31P NMR (202.46 MHz, DMSO-d6) δ 
18.80 ppm. HRMS (ESI) Calcd. for C13H31O6P2S [M+H]+ 377.1311; found 377.1324.
1-[(n-Dodecylthio)ethyl]-1,1-bisphosphonic acid (57). 80% yield; white solid; mp = 
110 ºC; 1H NMR (500.13 MHz, DMSO-d6) δ 0.84 (t, J = 7.0 Hz, 3H, H-15), 1.23 (m, 
16H, -CH2-), 1.30 (p, J = 7.6 Hz, 2H, H-6), 1.49 (p, J = 7.3 Hz, 2H, H-5), 2.10 (tt, J = 
22.5, 6.0 Hz, 1H, H-1), 2.84 (t, J =15.5, 6.1 Hz, 2H, H-2); 31P NMR (202.46 MHz, 
DMSO-d6) δ 18.97 ppm. HRMS (ESI) Calcd. for C14H33O6P2S [M+H]+ 391.1468; 
found 391.1453
  
1-[(n-Undecylsulfinyl)ethyl]-1,1-bisphosphonic acid (55). 81% yield; white solid; mp 
= 97 ºC; 1H NMR (500.13 MHz, D2O)  0.87 (t, J = 7.0 Hz, 3H, H-14), 1.20 (m, 12H, -
CH2-), 1.28 (p, J = 5.9 Hz, 2H, H-7), 1.39 (m, 2H, H-6), 1.69 (m, 2H, H-5), 2.39 (m, 
1H, H-1), 2.76 (ddd, J = 13.9, 8.5, 6.0 Hz, 1H, H-4a), 2.89 (ddd, J = 13.5, 8.4, 7.5 Hz, 
1H, H-4b), 3.15 (m, 2H, H-2); 31P NMR (202.46 MHz, D2O)  16.09 mAB. HRMS (ESI) 
Calcd. for C13H30O7P2SNa [M+Na]+ 415.1080; found 415.0797.
1-[(n-Dodecylsulfinyl)ethyl]-1,1-bisphosphonic acid (58). White solid, 67%; mp = 94 
ºC; 1H NMR (500.13 MHz, DMSO-d6)  0.84 (t, J = 7.0 Hz, 3H, H-15), 1.23 (m, 14H, -
CH2-), 1.38 (p, J = 6.9 Hz, 2H, H-6), 1.61 (p, J = 7.4 Hz, 2H, H-5), 2.57 (dt, J = 13.7, 
6.9 Hz, 1H, H-4a), 2.81 (dt, J = 13.1, 8.0 Hz, 1H, H-4b), 3.05 (m, 2H, H-2); 31P NMR 
(202.46 MHz, DMSO-d6)  17.31 mAB.
1-[(n-Undecylsulfonyl)ethyl]-1,1-biphosphonic acid (56). 58% yield; white solid; mp 
= 128 ºC; 1H NMR (500.13 MHz, DMSO-d6) δ 0.84 (t, J = 6.9 Hz, 3H, H-14), 1.22 (m, 
14H, CH2), 1.33 (p, J = 7.3 Hz, 2H, H-6), 1.65 (p, J = 7.7 Hz, 2H, H-5), 3.26 (m, 2H, 
H-4), 3.37 (t, J =16.3, 5.2 Hz, 2H, H-2); 31P NMR (202.46 MHz, DMSO-d6) δ 17.13 
ppm. HRMS (ESI) Calcd. for C13H31O8P2S [M+H]+ 409.1209; found 409.1198.
1-[(n-Dodecylsulfonyl)ethyl]-1,1-biphosphonic acid (59). 65% yield; white solid; mp 
125 ºC; 1H NMR (500.13 MHz, DMSO-d6) δ 0.84 (t, J = 6.9 Hz, 3H, H-15), 1.23 (m, 
14H, -CH2-),1.33 (p, J = 7.0 Hz, 2H, H-6), 1.64 (p, J = 7.6 Hz, 2H, H-5), 3.21 (m, 2H, 
H-4) 3.38 (dt, J = 16.1, 4.7 Hz, 1H, H-2); 13C NMR (125.77 MHz, DMSO-d6) δ 14.0 
(C-15), 21.5 (C-14), 22.1 (C-5), 27.8 (C-6), 28.6 (C-7), 28.76 (C-8), 28.84 (C-9), 29.0 
(C-12), 29.06 (C-10), 29.08 (C-11), 31.3 (C-13), 34.1 (t, J = 122.3 Hz, C-1), 49.7 (t, J = 
4.0 Hz, C-2), 52.5 (C-4); 31P NMR (202.46 MHz, DMSO-d6) δ 17.04 ppm. HRMS 
(ESI) Calcd. for C14H32O8P2SNa [M+Na]+ 445.1185; found 445.1201.
Drug Screening
T. cruzi amastigote assays
These experiments were done as reported using tdTomato labeled trypomastigotes 
with the modifications described by Recher et al., 2013.52 ED50 values were determined 
  
by non-linear regression analysis using SigmaPlot. 
T. gondii tachyzoites assays
Experiments on T. gondii tachyzoites were carried out as described previously 
using T. gondii tachyzoites expressing red fluorescent protein with the modifications 
described by Recher et al., 2013.52 Plates were read with covered lids, and both 
excitation (544 nm) and emission (590 nm) were read from the bottom. 
Cytotoxicity for Vero cells. The cytotoxicity was tested using the Alamar BlueTM assay 
as described by Recher et al., 2013.52 
TcFPPS and TgFPPS assays and product analysis. The enzymatic activity of the 
target enzymes was performed according to our previous studies as described for 
Szajnman et al., 2008.48 
Supplementary Data: Copies of the 1H NMR, 13C NMR and 31P NMR spectra of the 
target molecules and the corresponding intermediates are included as supporting 
information. 
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